Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras

Patients To Start Receiving The Drug In The Next Few Weeks

Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.

Lumakras (sotorasib) will soon be made available in England on the National Health Service for eligible lung cancer patients, following an early access agreement reached with the drug’s manufacturer, Amgen.

NHS England, Amgen and health technology assessment body NICE reached the deal to enable early access to the first-in-class, KRAS...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe